14.00 USD
↗ 1.81 (14.85%)AT CLOSE (11:59 AM EDT)
Q32 Bio Inc. Common Stock
QTTBNASDAQ • USD
14.19
↗ 0.19 (1.35%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
14.19
↗ 0.19 (1.35%)
Market: CLOSED
Open?$11.85
High?$14.85
Low?$11.85
Prev. Close?$12.19
Volume?1.1M
Avg. Volume?1.1M
VWAP?$13.82
Rel. Volume?0.95x
Bid / Ask
Bid?$14.10 × 700
Ask?$14.23 × 300
Spread?$0.13
Midpoint?$14.17
Valuation & Ratios
Market Cap?237.4M
Shares Out?17.0M
Float?5.6M
Float %?38.0%
P/E Ratio?7.14
P/B Ratio?5.13
EPS?$1.96
Dividend?0.00%
Ex-Dividend?N/A
Shares of Q32 Bio Inc. Common Stock (QTTB) are trading at $14.05. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (71.8%), a bullish Golden Cross on the moving averages and bullish moving average alignment. On the valuation side, QTTB appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Jun 4, 2026.
News
Profile
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Address
830 WINTER STREET
WALTHAM, MA 02451
Phone: 781-999-0232
WALTHAM, MA 02451
Phone: 781-999-0232
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?99
Momentum?77
Short Sent.?46
Piotroski F-Score?0/9Weak
Altman Z-Score?5.30Safe
Confidence?40%Low
Short InterestHigh
Short % of Float?11.39%High
Short Interest?632.7K
Days to Cover?2.7
Free Float5.6M
Avg Daily Volume236.7K
Settlement Date2026-05-15
Financial Health
Current Ratio?5.36Strong
Quick Ratio?5.36Strong
Cash Ratio?4.76Strong
Debt/Equity?0.18Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score80/100
P/E?7.1CHEAP▾
Peers100
S&P97
P/B?5.13FAIR▾
Peers100
S&P36
P/S?4.42FAIR▾
Peers100
S&P34
P/FCF?N/A▾
EV/EBITDA?9.0CHEAP▾
Peers100
S&P86
EV/Sales?3.63FAIR▾
Peers100
S&P52
Returns & Efficiency
ROE?71.8%STRONG▾
Peers50
S&P94
ROA?52.2%STRONG▾
Peers50
S&P97
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$194.8M
Fundamentals ratios updated end of day